Comparison of two different techniques to assess adalimumab trough levels in patients with Crohn’s disease

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 4, 2015, Pages 451-456

  Bodini, Giorgia ^a   Giannini, Edoardo G ^a   Furnari, Manuele ^a   Marabotto, Elisa ^a   Baldissarro, Isabella ^a   Nero, Lorenzo Del ^a   Assandri, Lorenzo ^a   Moscatelli, Alessandro ^a   Savarino, Vincenzo ^a   Savarino, Edoardo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

ELISA; HMSA; Inflammatory bowel disease; Loss of response

Indexed keywords

ADALIMUMAB; INFLIXIMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; ASSAY; CLINICAL ARTICLE; CROHN DISEASE; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOMOGENEOUS MOBILITY SHIFT ASSAY; HUMAN; MALE; RELAPSE; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; COMPARATIVE STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RECURRENT DISEASE; REMISSION; REPRODUCIBILITY; SIZE EXCLUSION CHROMATOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROHN DISEASE; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84949214218     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.244.adb     Document Type: Article

References (39)

1. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011; 33: 857-869. doi: 10.1111/j.1365-2036.2011.04598.x
2. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010; 45: 9-16. doi: 10.1007/s00535-009-0138-3
3. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis 2010; 16(Suppl 1): S1-11. doi: 10.1002/ibd.21529
4. Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol 2012; 47: 1298-1307. doi: 10.1007/s00535-012-0605-0
5. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92-101. doi: 10.1111/j.1365-2036.2009.04130.x
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549. doi: 10.1016/S0140-6736(02)08512-4
7. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885. doi: 10.1056/NEJMoa030815
8. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500. doi: 10.1136/gut.2008.155812
9. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868. doi: 10.1053/j.gastro.2008.03.004
10. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-767. doi: 10.1038/ajg.2008.88
11. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-698. doi: 10.1038/ajg.2011.103
12. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106: 674-684. doi: 10.1038/ajg.2011.60
13. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 349-358. doi: 10.1002/ibd.21831
14. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005; 313: 578-585. doi: 10.1124/jpet.104.079277
15. Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol (Basel) 2003; 112: 15-21.
16. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-1275. doi: 10.1002/ibd.20899
17. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol 2012; 47: 136-143. doi: 10.1007/s00535-011-0474-y
18. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2012; 108: 40-47. doi: 10.1038/ajg.2012.363
19. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-1640. doi: 10.1053/j.gastro.2009.07.062
20. Fasanmade A, Olson A, Bao W, et al. Relationship between infliximab pharmacokinetics and improvement in Crohn's disease. Gastroenterology 2002; 122 (4 Suppl 1): A617-A618.
21. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395. doi: 10.1056/NEJMoa0904492
22. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-926. doi: 10.1136/ard.2006.065615
23. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-1468. doi: 10.1001/jama.2011.406
24. Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2015. doi: 10.1136/gutjnl-2014-308099
25. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514. doi: 10.1016/S0140-6736(80)92767-1
26. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol 2005; 19(Suppl A): 5A-36A.
27. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 2013; 78-79: 39-44. doi: 10.1016/j.jpba.2013.01.031
28. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014; 109: 1250-1256. doi: 10.1038/ ajg.2014.146
29. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014; 109: 1055-1064. doi: 10.1038/ajg.2014.106
30. Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 2014; 20: 1714-1721. doi: 10.1097/MIB.0000000000000138
31. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-771. doi: 10.1111/apt.12030
32. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148: 1320-1329. doi: 10.1053/j.gastro.2015.02.031
33. Bodini G, Savarino V, Dulbecco P, Baldissarro I, Savarino E. The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF-α levels and clinical outcome. J Crohns Colitis 2014; 8 (Supplement 1): S42. doi: 10.1016/S1873-9946(14)60082-9
34. Bodini G, Savarino V, Dulbecco P, et al. Correlation between adalimumab trough serum concentration, anti-adalimumab antibodies and TNF-alfa levels with clinical outcome in patients affected by Crohn's Disease. Gastroenterology 2013; 144 (Supplement 1): S780. doi: 10.1016/ S0016-5085(13)62885-1
35. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. doi: 10.1053/j.gastro.2006.11.041
36. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239. doi: 10.1136/gut.2006.106781
37. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007; 25: 675-680. doi: 10.1111/j.1365-2036.2007.03254.x
38. Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2013; 7: 154-160. doi: 10.1016/j. crohns.2012.03.018
39. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014; 40: 620-628. doi: 10.1111/apt.12869